Prime Medicine, Inc.

Prime Medicine, Inc.

PRMENYSE / NASDAQHealthcareSmall cap

$3.55-$0.29 (-7.6%)

Last close · Data as of Nov 20, 2026

Market cap
$626.7M
P/E
-3.1x
EV / EBITDA
-3.4x
Revenue
$4.6M
Net margin
-4342.4%
ROCE
-68.2%

-3.8% over the last year

Prime Medicine, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-9.4%
3M
+9.6%
6M
+25.4%
1Y
-3.8%
5Y
Short history
  • A period is left blank when the price history is shorter than the period.

52-week range

Day change -$0.29 (-7.6%) from $3.84 to $3.55 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in PRME, bought on each weekday since 2022.

News & filings

What Prime Medicine filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 201 million US dollars in fiscal 2025.

Strengths (1)

  • Revenue grew 55.3% in fiscal 2025.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States.

Read moreShow less

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma. The company also provides vivo programs targeting diseases of the liver, and Cystic Fibrosis programs. In addition, it offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration and license agreement with BMS; Cystic Fibrosis Foundation; Broad Institute; and Beam. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Sector
Healthcare
Shares outstanding
180.5M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$626.7M
P/E
-3.1x
P/B
5.2x
EV / EBITDA
-3.4x
EV / Sales
146.8x
P/S
135.3x
52-week high
$5.36
52-week low
$2.70

Profitability

Operating margin
-4498.1%
Net margin
-4342.4%
EBITDA margin
-4340.0%
ROE
-166.4%
ROCE
-68.2%
ROIC
-94.5%
ROA
-58.7%
Asset turnover
0.01

Growth

Revenue
$4.6M
Revenue growth, 1Y
55.3%
Net profit growth, 1Y
2.7%
Free cash flow
-$167.1M

Solvency

Current ratio
4.84
Debt / Equity
0.96
Debt / Assets
0.34
CFO / Net profit
0.81
Cash / Market cap
10.1%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$4.6M
Gross profit$4.6M
Operating expenses$213.0M
Research and development$160.6M
Selling, general and administrative$52.4M
Operating income-$208.3M
Interest and other$7.2M
Pretax income-$201.1M
Tax and other$0.00
Net income-$201.1M

Revenue and net profit

Revenue grew 55.3% in FY2025; net profit is the dashed line.

Prime Medicine, Inc. revenue and net profit by fiscal year
Prime Medicine, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$0.00-$121.8M
FY2023$0.00-$198.1M
FY2024$3.0M-$195.9M
FY2025$4.6M-$201.1M

Cash flows

FY2025: -$162.6M from operations, -$167.1M free after investment (dashed).

Prime Medicine, Inc. operating and free cash flow by fiscal year
Prime Medicine, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$131.8M-$147.9M
FY2023-$165.4M-$174.1M
FY2024-$122.9M-$130.2M
FY2025-$162.6M-$167.1M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$4.6M+55.3%1Y
EBITDA
-$201.0M
Net profit
-$201.1M
Cash from operations
-$162.6M
Free cash flow
-$167.1M
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$4.6M-$201.0M-$201.1M-$167.1M-166.4%+55.3%+2.7%

Monthly returns

Month-by-month returns of PRME across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$342.7M
Liabilities$221.9M
Equity$120.9M
Paid-in capital$1.0B
Retained earnings-$888.4M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; PRME highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. Prime Medicine, Inc. (this company)146.8x

Not shown (no positive earnings and no EV / Sales): First Tracks Biotherapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Prime Medicine, Inc.PRMEthis company$626.7M-3.1x5.2x-166.4%-3.4x
Zevra Therapeutics, Inc.ZVRA$660.3M7.9x4.3x53.8%6.7x
SI-BONE, Inc.SIBN$659.9M—3.7x-10.6%—
Aclaris Therapeutics, Inc.ACRS$657.8M-10.1x6.4x-63.0%—
Castle Biosciences, Inc.CSTL$655.1M-27.1x1.4x-5.1%50.7x
First Tracks Biotherapeutics, Inc.TRAX$635.0M-3.9x1.6x-41.8%-3.0x
Beta Bionics, Inc.BBNX$619.0M-8.5x2.2x-25.5%-8.6x
Gyre Therapeutics, Inc.GYRE$600.6M119.5x5.7x4.7%40.3x
Phreesia, Inc.PHR$599.0M259.7x1.8x0.7%21.3x
Peer median—-3.9x2.9x-7.9%14.0x

Year-to-date ROI

PRME since 1 January, against earlier years.

Historical volatility

PRME's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Prime Medicine, Inc. operating margin by fiscal year
Prime Medicine, Inc. operating margin by fiscal year
DateOperating margin
FY2024-6794.3%
FY2025-4500.0%
LineFY2025
Operating expensesOperating Expense$213.0M
Research and developmentResearch And Development$160.6M
Total expensesTotal Expenses$213.0M
Pretax incomePretax Income-$201.1M

Learn while you research

Academy chapters picked for Prime Medicine, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Growth Investing55% revenue growth is in the top tier, learn how to value growth.7 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →